{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:01:53Z","timestamp":1790092913492,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006442","name":"Det Sundhedsvidenskabelige Fakultet, K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Copenhagen University","id":[{"id":"https:\/\/ror.org\/035b05819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01702-9","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:10:13Z","timestamp":1790089813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0856-4497","authenticated-orcid":false,"given":"Tianwu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9950-5911","authenticated-orcid":false,"given":"Maria","family":"Thastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-422X","authenticated-orcid":false,"given":"Tania Nicole","family":"Masmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-3767","authenticated-orcid":false,"given":"Hilde Hylland","family":"Uhlving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-7972","authenticated-orcid":false,"given":"Jacob","family":"Nersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0531-8531","authenticated-orcid":false,"given":"Malene Johanne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-2914","authenticated-orcid":false,"given":"Anna Sofie Buhl","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-4993","authenticated-orcid":false,"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-2880","authenticated-orcid":false,"given":"Trine Meldgaard","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1702_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","volume":"88","author":"R Lawson","year":"2021","unstructured":"Lawson R, Paterson L, Fraser CJ, Hennig S. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2021;88:379\u201391. https:\/\/doi.org\/10.1007\/s00280-021-04288-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1702_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","volume":"51","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, Boelens JJ, Bredius RGM, Egberts ACG, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet [Internet]. 2012;51:331\u201345. https:\/\/doi.org\/10.2165\/11598180-000000000-00000.","journal-title":"Clin Pharmacokinet [Internet]."},{"key":"1702_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","volume":"20","author":"JS McCune","year":"2014","unstructured":"McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NHG. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20:754\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1960.","journal-title":"Clin Cancer Res"},{"key":"1702_CR4","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant [Internet]. 1996;17:225\u201330.","journal-title":"Bone Marrow Transplant [Internet]"},{"key":"1702_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00888","volume":"11","author":"P Shukla","year":"2020","unstructured":"Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, et al. Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population. Front Pharmacol. 2020;11:888. https:\/\/doi.org\/10.3389\/fphar.2020.00888.","journal-title":"Front Pharmacol"},{"key":"1702_CR6","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EML, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol [Internet]. 2016;3:e526\u201336. https:\/\/doi.org\/10.1016\/S2352-3026(16)30114-4.","journal-title":"Lancet Haematol [Internet]"},{"key":"1702_CR7","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","volume":"17","author":"MN Trame","year":"2011","unstructured":"Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res. 2011;17:6867\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0074.","journal-title":"Clin Cancer Res"},{"key":"1702_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"J Palmer","year":"2016","unstructured":"Palmer J, McCune JS, Perales M-A, Marks D, Bubalo J, Mohty M, et al. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22:1915\u201325. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.013.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1702_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523\u201336. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.489.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1702_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008;14:220\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2007.10.028.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1702_CR11","unstructured":"European Medicines Agency. Busulfan Fresenius Kabi: EPAR-Product Information [Internet]. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/busulfan-fresenius-kabi#product-info. Accessed 11 Jul 2026"},{"key":"1702_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","volume":"37","author":"JR Long-Boyle","year":"2015","unstructured":"Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, et al. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015;37:236\u201345. https:\/\/doi.org\/10.1097\/FTD.0000000000000131.","journal-title":"Ther Drug Monit"},{"key":"1702_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071859","volume":"15","author":"P Del Valle-Moreno","year":"2023","unstructured":"Del Valle-Moreno P, Suarez-Casillas P, Mej\u00edas-Trueba M, Ciudad-Guti\u00e9rrez P, Guisado-Gil AB, Gil-Navarro MV, et al. Model-informed precision dosing software tools for dosage regimen individualization: a scoping review. Pharmaceutics. 2023;15:1859. https:\/\/doi.org\/10.3390\/pharmaceutics15071859.","journal-title":"Pharmaceutics"},{"key":"1702_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/cpt.3577","volume":"117","author":"S Huang","year":"2025","unstructured":"Huang S, Xu Q, Yang G, Ding J, Pei Q. Machine learning for prediction of drug concentrations: application and challenges. Clin Pharmacol Ther. 2025;117:1236\u201347. https:\/\/doi.org\/10.1002\/cpt.3577.","journal-title":"Clin Pharmacol Ther"},{"key":"1702_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081530","volume":"14","author":"L Keutzer","year":"2022","unstructured":"Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, et al. Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin. Pharmaceutics. 2022;14:1530. https:\/\/doi.org\/10.3390\/pharmaceutics14081530.","journal-title":"Pharmaceutics"},{"key":"1702_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70359","volume":"18","author":"A Rawal","year":"2025","unstructured":"Rawal A, Ou J, Zhu H, Sauna Z, Tegenge MA. Utilization of machine learning approaches for drug clearance prediction and population pharmacokinetic covariate analysis. Clin Transl Sci. 2025;18:e70359. https:\/\/doi.org\/10.1111\/cts.70359.","journal-title":"Clin Transl Sci"},{"key":"1702_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105578","volume":"167","author":"J-B Woillard","year":"2021","unstructured":"Woillard J-B, Labriffe M, Pr\u00e9maud A, Marquet P. Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus. Pharmacol Res. 2021;167:105578. https:\/\/doi.org\/10.1016\/j.phrs.2021.105578.","journal-title":"Pharmacol Res"},{"key":"1702_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cpt.2123","volume":"110","author":"J-B Woillard","year":"2021","unstructured":"Woillard J-B, Labriffe M, Debord J, Marquet P. Tacrolimus exposure prediction using machine learning. Clin Pharmacol Ther. 2021;110:361\u20139. https:\/\/doi.org\/10.1002\/cpt.2123.","journal-title":"Clin Pharmacol Ther"},{"key":"1702_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/cpt.2794","volume":"113","author":"JS McCune","year":"2023","unstructured":"McCune JS, Navarro SL, Baker KS, Risler LJ, Phillips BR, Randolph TW, et al. Prediction of busulfan clearance by predose plasma metabolomic profiling. Clin Pharmacol Ther. 2023;113:370\u20139. https:\/\/doi.org\/10.1002\/cpt.2794.","journal-title":"Clin Pharmacol Ther"},{"key":"1702_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","volume":"60","author":"R Lawson","year":"2021","unstructured":"Lawson R, Staatz CE, Fraser CJ, Hennig S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet. 2021;60:17\u201351. https:\/\/doi.org\/10.1007\/s40262-020-00947-2.","journal-title":"Clin Pharmacokinet"},{"key":"1702_CR21","first-page":"777","volume":"137","author":"S Desire","year":"2013","unstructured":"Desire S, Mohanan EP, George B, Mathews V, Chandy M, Srivastava A, et al. A rapid & sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation. Indian J Med Res [Internet]. 2013;137:777\u201384.","journal-title":"Indian J Med Res [Internet]"},{"key":"1702_CR22","doi-asserted-by":"publisher","first-page":"1007.e1","DOI":"10.1016\/j.jtct.2024.07.015","volume":"30","author":"T Bogn\u00e0r","year":"2024","unstructured":"Bogn\u00e0r T, Bartelink IH, van der Elst KCM, Kingma JS, Smeijsters EH, Lindemans CA, et al. Busulfan exposure target attainment in adults undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiple day therapeutic drug monitoring regimen. Transplant Cell Ther. 2024;30:1007.e1-1007.e10. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.015.","journal-title":"Transplant Cell Ther"},{"key":"1702_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JHM, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3:e00131. https:\/\/doi.org\/10.1002\/prp2.131.","journal-title":"Pharmacol Res Perspect"},{"key":"1702_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","volume":"10","author":"DJ Irby","year":"2021","unstructured":"Irby DJ, Ibrahim ME, Dauki AM, Badawi MA, Illamola SM, Chen M, et al. Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics. CPT Pharmacomet Syst Pharmacol. 2021;10:291\u2013308. https:\/\/doi.org\/10.1002\/psp4.12611.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1702_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"C-Y Zhao","year":"2016","unstructured":"Zhao C-Y, Jiao Z, Mao J-J, Qiu X-Y. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81:891\u2013907. https:\/\/doi.org\/10.1111\/bcp.12830.","journal-title":"Br J Clin Pharmacol"},{"key":"1702_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bcp.13431","volume":"84","author":"J-J Mao","year":"2018","unstructured":"Mao J-J, Jiao Z, Yun H-Y, Zhao C-Y, Chen H-C, Qiu X-Y, et al. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients. Br J Clin Pharmacol. 2018;84:153\u201371. https:\/\/doi.org\/10.1111\/bcp.13431.","journal-title":"Br J Clin Pharmacol"},{"key":"1702_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020665","volume":"15","author":"C Leven","year":"2023","unstructured":"Leven C, M\u00e9nard P, Gouin-Thibault I, Ballerie A, Lacut K, Ollier E, et al. Transferability of published population pharmacokinetic models for apixaban and rivaroxaban to subjects with obesity treated for venous thromboembolism: a systematic review and external evaluations. Pharmaceutics. 2023;15:665. https:\/\/doi.org\/10.3390\/pharmaceutics15020665.","journal-title":"Pharmaceutics"},{"key":"1702_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106915","volume":"203","author":"R Li","year":"2024","unstructured":"Li R, Sun F, Feng Z, Zhang Y, Lan Y, Yu H, et al. Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients. Eur J Pharm Sci. 2024;203:106915. https:\/\/doi.org\/10.1016\/j.ejps.2024.106915.","journal-title":"Eur J Pharm Sci"},{"key":"1702_CR29","unstructured":"Lundberg S, Lee S-I. A unified approach to interpreting model predictions. 2017; http:\/\/arxiv.org\/abs\/1705.07874"},{"key":"1702_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","volume":"28","author":"T Bogn\u00e0r","year":"2022","unstructured":"Bogn\u00e0r T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, et al. Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:196\u2013202. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.013.","journal-title":"Transplant Cell Ther"},{"key":"1702_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04757-w","volume":"95","author":"FM Balis","year":"2025","unstructured":"Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, et al. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. Cancer Chemother Pharmacol. 2025;95:32. https:\/\/doi.org\/10.1007\/s00280-025-04757-w.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1702_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/bcp.14256","volume":"86","author":"JB Langenhorst","year":"2020","unstructured":"Langenhorst JB, Boss J, van Kesteren C, Lalmohamed A, Kuball J, Egberts ACG, et al. A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. Br J Clin Pharmacol. 2020;86:1499\u2013509. https:\/\/doi.org\/10.1111\/bcp.14256.","journal-title":"Br J Clin Pharmacol"},{"key":"1702_CR33","doi-asserted-by":"publisher","first-page":"104.e1","DOI":"10.1016\/j.jtct.2021.11.018","volume":"28","author":"T Takahashi","year":"2022","unstructured":"Takahashi T, Illamola SM, Jennissen CA, Long SE, Lund TC, Orchard PJ, et al. Busulfan dose recommendation in inherited metabolic disorders: population pharmacokinetic analysis. Transplant Cell Ther. 2022;28:104.e1-104.e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.11.018.","journal-title":"Transplant Cell Ther"},{"key":"1702_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ajh.24734","volume":"92","author":"S-J Rhee","year":"2017","unstructured":"Rhee S-J, Lee JW, Yu K-S, Hong KT, Choi JY, Hong CR, et al. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. Am J Hematol. 2017;92:607\u201313. https:\/\/doi.org\/10.1002\/ajh.24734.","journal-title":"Am J Hematol"},{"key":"1702_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/psp4.12809","volume":"11","author":"R Lawson","year":"2022","unstructured":"Lawson R, Staatz CE, Fraser CJ, Ramachandran S, Teague L, Mitchell R, et al. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance. CPT Pharmacomet Syst Pharmacol. 2022;11:1002\u201317. https:\/\/doi.org\/10.1002\/psp4.12809.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1702_CR36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40262-023-01275-x","volume":"62","author":"T Takahashi","year":"2023","unstructured":"Takahashi T, Jaber MM, Brown SJ, Al-Kofahi M. Population pharmacokinetic model of intravenous busulfan in hematopoietic cell transplantation: systematic review and comparative simulations. Clin Pharmacokinet. 2023;62:955\u201368. https:\/\/doi.org\/10.1007\/s40262-023-01275-x.","journal-title":"Clin Pharmacokinet"},{"key":"1702_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/17425255.2023.2192924","volume":"19","author":"D Combarel","year":"2023","unstructured":"Combarel D, Tran J, Delahousse J, Vassal G, Paci A. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions. Expert Opin Drug Metab Toxicol. 2023;19:75\u201390. https:\/\/doi.org\/10.1080\/17425255.2023.2192924.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01702-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:10:16Z","timestamp":1790089816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01702-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":37,"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01702-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Permission was obtained from the Team for Journal Data (R-24059676), Research Ethics and Research Support, Capital Region of Denmark, to access and process relevant patient health information and other confidential personal data from medical records for research purposes without obtaining individual informed consent from the included patients or their legal guardians. Data from the University Medical Centre Utrecht and the Princess M\u00e1xima Centre for Paediatric Oncology, both in Utrecht, the Netherlands, have been shared for validation purposes upon reasonable request by C.A. Lindemans, R. Admiraal and T. Bognar. The Dutch data were sampled after ethical committee approval under number 11\/063-k by the Medical Ethical Committee in Utrecht.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kjeld Schmiegelow received speaker and\/or Advisory Board Honoraria from Illumina (2021), Jazz Pharmaceuticals (2021, 2023) and Servier (2021, 2023, 2025). Kjeld Schmiegelow received speaker fees from Amgen (2021, 2023, 2025) and Medscape (2021), educational grants from Servier (2021, 2023, 2025) and SERB (2025), and research grants from Novo Nordisk Foundation (2020, 2022). Kjeld Schmiegelow has stocks in Novo Nordisk. All other authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to GDPR and institutional privacy regulations, the clinical data underlying this study cannot be made publicly available. However, the data that support the findings of this study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.Y., M.T., K.S., and T.M.L. conceptualised the study. T.Y., M.T., T.N.M., H.H.U., J.N., M.J.P., R.A., and A.S.B.R. curated the data. T.Y. performed the formal analysis, developed the methodology and software, validated and visualised the data, and wrote the original draft of the manuscript. M.T., T.N.M., H.H.U., J.N., M.J.P., A.S.B.R., K.S., and T.M.L. provided resources and reviewed and edited the manuscript. K.S. and T.M.L. acquired the funding, administered the project, and supervised the study. All authors read and approved the final version of the manuscript.","order":4,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research is funded by the University of Copenhagen and the Copenhagen University Hospital.","order":5,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}